Amaros

Executive Summary

Amaros is a US-based biotech company specializing in ophthalmology, offering a proprietary precision intelligence platform called AmarosEngine™. The platform integrates real-world clinical data from electronic health records (EHRs), practice management systems, and imaging sources to generate actionable insights. Its solutions aim to connect patients with optimal therapeutic interventions, supporting clinical trials, real-world evidence generation, and commercial growth for life sciences companies. Founded in 2021 and headquartered in San Francisco, Amaros operates in the AI and drug discovery sectors, leveraging data-driven approaches to address unmet needs in eye care. While Amaros has yet to disclose funding or revenue details, its focus on a niche therapeutic area with high data complexity positions it well for partnerships with pharmaceutical companies seeking real-world evidence. The company's ability to integrate diverse data sources could differentiate it in the competitive precision medicine landscape. However, execution risks remain, including data access challenges and the need for clinical validation. Overall, Amaros presents a compelling but early-stage opportunity in ophthalmology AI.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with a Top Ophthalmology Pharma40% success
• Q4 2026Launch of New Retinal Disease Module50% success
• Q2 2026Series A Funding Round60% success